---
title: A study to learn more about the long-term safety and efficacy of AB-1005 gene therapy in people with Parkinson’s disease or multiple system atrophy
euct_id: 2025-522653-19-00
status: Not yet recruiting
sponsor: Askbio Inc.
canonical_url: "https://parkinsonspathways.com/trials/eu/2025-522653-19-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2025-522653-19-00"
ctis_last_updated: "2026-03-27T02:33:07.330846109"
source: EU Clinical Trials Information System (CTIS)
---
# A study to learn more about the long-term safety and efficacy of AB-1005 gene therapy in people with Parkinson’s disease or multiple system atrophy

**EU CT Number:** [2025-522653-19-00](https://euclinicaltrials.eu/ctis-public/view/2025-522653-19-00)

## Key Facts

- **Status:** Not yet recruiting
- **Sponsor:** Askbio Inc.
- **Start Date:** 2026-12-01
- **Completion Date:** 2037-12-01
- **Conditions:** Multiple System Atrophy, Parkinson's Disease
- **Interventions:** Fluorodopa (18F), AAV2-GDNF, Carbidopa

## Member States

Trial is authorized in 1 member state: Poland.

## Sites (2)

- Specjalistyczna Praktyka Lekarska Prof. Grzegorz Opala, Katowice, Poland
- Copernicus Podmiot Leczniczy Sp. z o.o., Gdansk, Poland

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Multiple System Atrophy; Parkinson's Disease
Age groups: elderly 65+, adults 18-64
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2025-522653-19-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2025-522653-19-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2025-522653-19-00*